References
- Lu G, Middleton RE, Sun H, et al., The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 343(6168): 305–309. 2014. .
- Galustian C, Meyer B, Labarthe M-C, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother CII. 2009;58(7):1033–1045. .
- Luptakova K, Rosenblatt J, Glotzbecker B, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother CII. 2013;62:39–49.
- Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22–32.
- D’Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91(9):4082–4085.
- Kenyon BM, Browne F, D’Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997;64(6):971–978.
- Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–1791.
- McCarthy PL, Owzar K, Hofmeister CC, et al., Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 366(19): 1770–1781. 2012..
- Okazuka K, Ishida T, Nashimoto J, et al. The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Eur J Haematol. 2020Feb;104(2):110-115.
- Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106(1):35–39.
- Facon T, Mary J-Y, Pégourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood [Internet]. 2006;107(4):1292–1298. [cited 2019 Dec 22]. Available from: https://ashpublications.org/blood/article/107/4/1292/133650/Dexamethasone-based-regimens-versus-melphalan.
- Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337–1341. .
- Mai EK, Bertsch U, Dürig J, et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015;29(8):1721–1729. .
- Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol [Internet]. 2019;20(1):57–73. [cited 2019 Dec 19]. Available from: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30687-9/abstract.
- Garfall AL, Dougherty AL, Vogl DT, et al. Association between mobilization regimen and PFS after auto-SCT for multiple myeloma. Bone Marrow Transplant. 2014;49(11):1439–1441.
- Bergsagel DE, Sprague CC, Austin C, et al. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806). 1962;21:87–99.Cancer Chemother Rep
- Mateos M-V, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet [Internet]. 2019. [cited 2019 Dec 11]. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32956-3/abstract
- Landgren O. Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study. ASH; 2019. [cited 2019 Dec 11]. Available from https://ash.confex.com/ash/2019/webprogram/Paper126378.html
- Gagelmann N, Eikema D-J, Koster L, et al. Tandem autologous stem cell transplantation improves outcomes in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the chronic malignancies working party of the european society for blood and marrow transplantation. Biol Blood Marrow Transplant [Internet]. 2019;25(11):2134–2142. [cited 2019 Nov 18]. Available from: https://www.bbmt.org/article/S1083-8791(19)30436-7/abstract.
- Ma Y, Hendershot LM. The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer. 2004;4(12):966–977.
- Harousseau J-L, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(30):4621–4629. .
- Durie BGM, Hoering A, Abidi MH, et al., Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet Lond Engl. 389(10068): 519–527. 2017..
- Emery EC, Wood JN. Gaining on Pain. N Engl J Med. 2018;379(5):485–487.
- Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–440. .
- Bastidas A, de la Serna J, El Idrissi M, et al. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA. 2019;322(2):123–133.
- Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152. .
- Moreau P, Mateos M-V, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953–964. .
- Landgren O, Siegel DS, Auclair D, et al. Carfilzomib-lenalidomide-dexamethasone versus bortezomib-lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma: results from the prospective, longitudinal, observational commpass study. Blood [Internet]. 2018;132(Supplement 1):799. [cited 2020 Jan 13]. Available from: https://ashpublications.org/blood/article/132/Supplement 1/799/266209/Carfilzomib-Lenalidomide-Dexamethasone-Versus.
- Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–2115. .
- Gay F, Cerrato C, Petrucci MT, et al. Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: results from the FORTE trial. J Clin Oncol [Internet]. 2019;37(15_suppl):8002. [cited 2019 Dec 14]. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.8002.
- Yong K. Efficacy and safety of carfilzomib at 56mg/m2 with cyclophosphamide and dexamethasone (K56Cd) in newly diagnosed multiple myeloma patients followed by ASCT or K56Cd consolidation: initial results of the phase 2 cardamon study. ASH; 2019. [cited 2019 Dec 24]. Available from: https://ash.confex.com/ash/2019/webprogram/Paper127992.html
- Kubiczkova L, Pour L, Sedlarikova L, et al. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med. 2014;18(6):947–961. .
- Moreau P, Masszi T, Grzasko N, et al. oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–1634. .
- Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Lond Engl. 2019;393(10168):253–264. .
- Stansborough RL, Gibson RJ. Proteasome inhibitor-induced gastrointestinal toxicity. Curr Opin Support Palliat Care. 2017;11(2):133–137.
- Morandi F, Horenstein AL, Costa F, et al. CD38: a target for immunotherapeutic approaches in multiple myeloma. Front Immunol. 2018;9:2722.
- de Weers M, Tai Y-T, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol (Baltimore, MD) 1950. 2011;186:1840–1848.
- Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet Lond Engl. 2019;394(10192):29–38. .
- Voorhees P. Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVd) Improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): griffin study update. ASH; 2019. [cited 2019 Nov 23]. Available from https://ash.confex.com/ash/2019/webprogram/Paper123465.html
- Saleh ASA, Sidiqi MH, Gertz MA, et al. Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. Am J Hematol [Internet]. 2020;95(1):E8–E10. [cited 2020 Feb 28]. Available from: http://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25654.
- Costa L. Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, measurable residual disease (MRD)-based dara-krd consolidation in patients with newly diagnosed multiple myeloma (NDMM). ASH; 2019. [cited 2019 Dec 11]. Available from: https://ash.confex.com/ash/2019/webprogram/Paper123170.html
- Meeting Library. Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS) [Internet]. [cited 2019 Nov 23]. Available from: https://meetinglibrary.asco.org/record/178058/abstract.
- Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet Lond Engl. 2019;394(10214):2096–2107.
- A phase I/IIa study of human anti-CD38 antibody MOR03087 (MOR202) in relapsed/refractory multiple myeloma - full text view - clinicalTrials.gov [Internet] [cited 2020 Mar 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT01421186.
- Krishnan AY, Patel KK, Hari P, et al. Preliminary results from a phase 1b Study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/refractory multiple myeloma (RRMM). Blood [Internet]. 2019;134(Supplement_1):140. [cited 2020 Mar 16]. Available from: https://ashpublications.org/blood/article/134/Supplement_1/140/426135/Preliminary-Results-from-a-Phase-1b-Study-of-TAK.
- Tai Y-T, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329–1337. .
- Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(9):2775–2784. .
- van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009;8(9):2616–2624.
- Zonder JA, Mohrbacher AF, Singhal S, et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552–559. .
- Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631.
- Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379(19):1811–1822. .
- Touzeau C, Maciag P, Amiot M, et al. Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia. 2018;32(9):1899–1907. .
- Gomez-Bougie P, Maiga S, Tessoulin B, et al. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. Blood. 2018;132(25):2656–2669. .
- Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133(7):660–675. .
- Moreau P. Updated analysis of bellini, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. ASH; 2019. [cited 2020 Jan 2]. Available from: https://ash.confex.com/ash/2019/webprogram/Paper126015.html
- Suen H, Brown R, Yang S, et al. Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade. Leukemia [Internet]. 2016;30(8):1716–1724. [cited 2020 Feb 22]. Available from: http://www.nature.com/articles/leu201684.
- Hillengass J, Fechtner K, Weber M-A, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(9):1606–1610. .
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–548. .
- Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med [Internet]. 2011;365(5):474–475. [cited 2019 Dec 14]. Available from.
- Dutta AK, Fink JL, Grady JP, et al., Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia. 33(2): 457–468. 2019..
- Dhodapkar MV, Kelly T, Theus A, et al. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol. 1997;99(2):368–371.
- Frigyesi I, Adolfsson J, Ali M, et al. Robust isolation of malignant plasma cells in multiple myeloma. Blood. 2014;123(9):1336–1340.
- Jagannath S, Heffner LT, Ailawadhi S, et al. Indatuximab RAVtansine (BT062) monotherapy in patients with relapsed and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk [Internet]. 2019;19(6):372–380. [cited 2020 Mar 14]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2152265018315660.
- Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149–157. .
- Spencer A, Lentzsch S, Weisel K, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica [Internet]. 2018;103(12):2079–2087. [cited 2020 Mar 14]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269293/.
- Dimopoulos MA, San-Miguel J, Belch A, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica [Internet]. 2018;103(12):2088–2096. [cited 2020 Mar 14]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269302/.
- Madduri D, Usmani SZ, Jagannath S, et al. Results from CARTITUDE-1: a phase 1b/2 Study of JNJ-4528, a CAR-T cell therapy directed against b-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM). Blood [Internet]. 2019;134(Supplement_1):577. [cited 2020 Mar 15]. Available from: https://ashpublications.org/blood/article/134/Supplement_1/577/426449/Results-from-CARTITUDE-1-A-Phase-1b-2-Study-of-JNJ.
- Wang B-Y, Zhao W-H, Liu J, et al. Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting b-cell maturation antigen (BCMA), in Patients (pts) with relapsed/refractory multiple myeloma (RRMM). Blood [Internet]. 2019;134:579. [cited 2020 Mar 15]. Available from: https://ashpublications.org/blood/article/134/Supplement_1/579/426466/Long-Term-Follow-up-of-a-Phase-1-First-in-Human
- Sanchez E, Li M, Kitto A, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158(6):727–738. .
- Pont MJ, Hill T, Cole GO, et al. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood [Internet]. 2019;134(19):1585–1597. [cited 2020 Mar 15]. Available from: https://ashpublications.org/blood/article/134/19/1585/374996/Secretase-inhibition-increases-efficacy-of-BCMA.
- Bensinger W, Raptis A, Berenson JR, et al. Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma. J Clin Oncol [Internet]. 2019;37(15_suppl):8012. [cited 2020 Jan 18]. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.8012.
- Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med [Internet]. 2019;11(485):eaau7746. [cited 2020 Jan 18]. Available from: https://stm.sciencemag.org/content/11/485/eaau7746.
- Study to Evaluate CCS1477 in haematological malignancies - full text view - clinicalTrials.gov [Internet]. [cited 2020 Jan 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT04068597.
- Olson M, Radhakrishnan SV, Luetkens T, et al. The role of surface molecule CD229 in Multiple Myeloma. Clin Immunol [Internet]. 2019;204:69–73. [cited 2020 Mar 14]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1521661618305680.
- Radhakrishnan SV, Luetkens T, Scherer SD, et al. CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nat Commun [Internet]. 2020;11(1):798. [cited 2020 Mar 14]. Available from: http://www.nature.com/articles/s41467-020-14619-z.
- Kellner J, Wallace C, Liu B, et al. Definition of a multiple myeloma progenitor population in mice driven by enforced expression of XBP1s. JCI Insight. 2019;4(7). doi:10.1172/jci.insight.124698.
- Matsui W, Borrello I, Mitsiades C. Autologous stem cell transplantation and multiple myeloma cancer stem cells. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2012;18(1):S27–32.
- Khoo WH, Ledergor G, Weiner A, et al. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. Blood [Internet]. 2019;134(1):30–43. [cited 2020 Mar 15]. Available from: https://ashpublications.org/blood/article/134/1/30/260664/A-niche-dependent-myeloid-transcriptome-signature.
- Research C for DE and. FDA approves isatuximab-irfc for multiple myeloma. FDA [Internet]. 2020 [cited 2020 Mar 14]. Available from: http://www.fda.gov/drugs/development-approval-process-drugs/fda-approves-isatuximab-irfc-multiple-myeloma.
- Cohen AD, Garfall AL, Dogan A, et al. Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. Blood Adv [Internet]. 2019;3(16):2487–2490. [cited 2020 Mar 15]. Available from: https://ashpublications.org/bloodadvances/article/3/16/2487/260524/Serial-treatment-of-relapsed-refractory-multiple.
- van de Donk NWCJ, Usmani SZ. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol. 2018;9:2134.